MariMed Inc (MRMD) P/S Ratio
MariMed Inc (MRMD) has a price-to-sales ratio of 0.14x, placing it in the Deep Value range for cannabis stocks. The company has a market cap of $22.6M and TTM revenue of $163.8M. Revenue is growing 4.4% YoY.
P/S Ratio (TTM)
0.14x
EV/Revenue
0.59x
Market Cap
$22.6M
Revenue Growth
+4.4%
Valuation Breakdown
| Metric | Value |
|---|---|
| Stock Price | $0.0560 |
| Market Capitalization | $22.6M |
| TTM Revenue | $163.8M |
| Price-to-Sales (TTM) | 0.14x |
| EV/Revenue | 0.59x |
| Revenue Growth (YoY) | +4.4% |
| Gross Margin | 35.6% |
| Sector | MSO |
| Exchange | OTC |
| Valuation Range | Deep Value |
Frequently Asked Questions
What is MRMD's current price-to-sales ratio?+
The price-to-sales (P/S) ratio divides MariMed Inc's market capitalization by its trailing twelve months of revenue. Since many cannabis companies are not yet profitable, P/S is one of the most widely used valuation metrics in the sector. A lower ratio may suggest the stock is undervalued relative to revenue.
How does MRMD's P/S compare to other cannabis stocks?+
P/S ratios in cannabis typically range from 0.5x to 5x depending on growth rate, profitability, and market sentiment. High-growth companies command higher multiples, while mature, lower-growth companies trade at lower multiples. Compare MariMed Inc to peers in the same sub-sector (MSO, LP, ancillary) for meaningful context.
Is MRMD overvalued or undervalued based on P/S?+
A single metric like P/S cannot definitively determine if MariMed Inc is over- or undervalued. Consider P/S alongside revenue growth rate, gross margins, cash position, and competitive dynamics. A company growing revenue at 50% YoY may justify a higher P/S than one growing at 5%. Also consider enterprise value-to-revenue (EV/Revenue) which accounts for debt and cash.